A New Optimized Percutaneous Access System for CIPII. (July 2017)

• Record Type: Journal Article
• Authors: Garcia-Verdugo, Rosa; Erbach, Michael; Schnell, Oliver
• Is Part Of: Journal of diabetes science and technology. Volume 11:Number 4(2017:Jul.)
• Page Start: 814
• Page End: 821
• Publication Date: 2017-07
• Subjects: CIPII -- hypoglycemia -- subcutaneous insulin resistance -- type 1 diabetes; Diabetes -- Periodicals; Medical technology -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1177/1932296817694913
• Languages: English
• ISSNs: 1932-2968

Abstract

In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a favored treatment alternative for patients with subcutaneous insulin resistance, mainly due to its ability of mimicking physiological conditions of insulin absorption. CIPII has been shown to improve glycemic control as well as to reduce hypoglycemic events and to lead to increased patient satisfaction and quality of life (QoL). Among CIPII delivery systems, Diaport stands out due to its low side effects, its demonstrated clinical efficacy and the potential for integration into closed-loop systems.